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Exotropia (SamExo): study protocol for a pilot
randomised controlled trial
Deborah Buck1*, Elaine McColl2, Christine J Powell3, Jing Shen2, John Sloper4, Nick Steen2, Robert Taylor5,
Peter Tiffin6, Luke Vale2 and Michael P Clarke3,7Abstract
Background: Childhood intermittent exotropia [X(T)] is a type of strabismus (squint) in which one eye deviates
outward at times, usually when the child is tired. It may progress to a permanent squint, loss of stereovision and/or
amblyopia (reduced vision). Treatment options for X(T) include eye patches, glasses, surgery and active monitoring.
There is no consensus regarding how this condition should be managed, and even when surgery is the preferred
option clinicians disagree as to the optimal timing. Reports on the natural history of X(T) are limited, and there is
no randomised controlled trial (RCT) evidence on the effectiveness or efficiency of surgery compared with active
monitoring. The SamExo (Surgery versus Active Monitoring in Intermittent Exotropia) pilot study has been designed
to test the feasibility of such a trial in the UK.
Methods: Design: an external pilot patient randomised controlled trial.
Setting: four UK secondary ophthalmology care facilities at Newcastle NHS Hospitals Foundation Trust, Sunderland
Eye Infirmary, Moorfields Eye Hospital and York NHS Trust.
Participants: children aged between 6 months and 16 years referred with suspected and subsequently diagnosed X
(T). Recruitment target is a total of 144 children over a 9-month period, with 120 retained by 9-month
outcome visit.
Randomisation: permuted blocks stratified by collaborating centre, age and severity of X(T).
Interventions: initial clinical assessment; randomisation (eye muscle surgery or active monitoring); 3-, 6- and
9-month (primary outcome) clinical assessments; participant/proxy completed questionnaire covering time and
travel costs, health services use and quality of life (Intermittent Exotropia Questionnaire); qualitative interviews with
parents to establish reasons for agreeing or declining participation in the pilot trial.
Outcomes: recruitment and retention rates; nature and extent of participation bias; nature and extent of biases
arising from crossover or loss to follow-up; reasons for agreeing/declining participation; variability of cure rates
(to inform power calculations for a definitive RCT); completion rates of outcome measures.
Discussion: The SamExo pilot trial will provide important pointers regarding the feasibility of a full RCT of
immediate surgery versus deferred surgery/active monitoring. The results of this pilot, including differences in cure
rates, will inform the design of a definitive RCT.
Trial registration: ISRCTN44114892
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Strabismus, also known as squint, is an ophthalmic con-
dition in which the eyes are misaligned and therefore
look in different directions: that is, one eye looks straight
ahead while the other turns either outward (exotropia),
inward (esotropia), upward (hypertropia) or downward
(hypotropia) [1]. It may be constant, with loss of binocu-
lar function, or intermittent, with binocular function
when the squint is not present. Squint can occur in chil-
dren or adults and may have functional, aesthetic and
psychosocial consequences [2-16]. For example, teen-
agers and adults with squint have reported problems
with self-esteem, self-image and interpersonal relation-
ships, have met ridicule at school or work, and may at-
tempt to avoid activities that bring attention to their
condition or to develop strategies that conceal it [8,10].
Similarly in young children, squint has been linked to
lower psychosocial functioning, poorer interpersonal
relationships and lower self-esteem [15,16]. It has been
shown that children as young as 5 years are significantly
more likely to have negative social reactions to peers
with strabismus [13,14] and that teachers rate photo-
graphs of children with strabismus more negatively than
those with straight eyes [15].
Parents may seek treatment for their child’s squint out
of concern that abnormal ocular alignment could result
in social exclusion and bullying [6]. However, conserva-
tive treatment with eye patches [17-19] or glasses may in
itself negatively affect the child’s psychosocial well-being
and lead to increased bullying and stigmatisation
[6,11,20,21]. As Menon et al. [8] report, these problems
sometimes remain through to adulthood. Parents of chil-
dren with squint may themselves experience a negative
impact on their own psychological well-being, parental
role, family functioning and general functioning [22,23].
Intermittent exotropia [X(T)] is one of the commonest
types of childhood strabismus [24,25]. In this condition,
one eye intermittently drifts outward. It is possible for
X(T) to develop into a constant squint (XT) [24,25] and
lead to loss of stereovision and/or the development of
amblyopia [18] (reduced acuity in one eye caused by
decreased quality visual input during the critical period
of development). Typically, X(T) is first spotted in early
childhood by parents noticing that their child’s eye is
wandering outward as they look at objects in the dis-
tance or when they are very tired, inattentive or in bright
sunlight.
Conservative treatment options for X(T) include
occlusion with eye patches or wearing glasses that
stimulate convergence. Eye muscle surgery can also be
performed in order to realign the eyes. However, many
clinicians and parents opt for an active monitoring
approach, that is, they decide to wait and see whether
the squint resolves spontaneously or at the very leastdoes not deteriorate. Long-term natural history data are
lacking, but there is some indication from observational
work that X(T) surgery is more successful than conser-
vative treatment and active monitoring in improving
control of the eyes [19]. However, the success of surgery
is not guaranteed: it comes with a risk of over-correction
whereby the eye alignment converts to a constant con-
vergent deviation (esotropia) with a consequent loss of
function in terms of stereovision and the potential to de-
velop amblyopia in young children or diplopia (double
vision) in older children. Alternatively, an under-
correction may occur with persistence of the X(T).
There is also evidence that the effectiveness of surgery
declines over time [26]. There is considerable variability
in rates of surgery and a lack of consistency in the surgi-
cal indications for treatment of X(T) in the UK [18,19].
Here, the majority of children with the condition do not
appear to undergo eye muscle surgery within 2 years of
presentation and instead are monitored recurrently, with
significant loss to clinical follow-up.
Surgical intervention and active monitoring together
incur substantial costs to the UK National Health Ser-
vice (NHS). For example, over 6,000 procedures were
performed by the NHS on children under 16 years in
2007/8, of which around 1,000 are estimated to have
been performed for X(T). The tariff rate for strabismus
surgery is £800, and together with approximately
100,000 clinic visits annually for review of patients with
X(T) (at a tariff cost of £120 per new patient and £60
per review: estimated average new:review ratio 1:8), the
total cost to the NHS alone is almost £7.5 million annu-
ally. With the inclusion of societal and family costs, the
management of X(T) is more costly. Our previous co-
hort study [18,19] has demonstrated not only consider-
able variability in management between centres, but also
a ‘therapeutic inertia’, with many children receiving no
active treatment and many eventually defaulting from
follow-up, contributing to high DNA (did not attend)
rates. Without further research, inefficiencies in the use
of NHS and societal resources used to manage X(T) are
likely to remain.
The lack of trial-based evidence means that the true
effectiveness of treatment in ameliorating or curing the
condition is unknown. Moreover, even when surgery is
the preferred course of action there is little agreement
on whether immediate surgery is more effective than
delaying the operation for a specified length of time or
until a certain age. A pressing need for carefully planned
clinical trials of treatment to improve the evidence base
for the management of this condition has previously
been identified [27].
The current investigators hope to conduct such a trial,
if feasible. Since the recruitment phase in any trial is one
of the most challenging [28,29], and given the potential
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[30-33] or surgical [34] trials, we are first undertaking
the SamExo (Surgery versus Active Monitoring in Inter-
mittent Exotropia) pilot trial in order to assess feasibility
and inform the design and conduct of a full-scale trial
(http://research.ncl.ac.uk/samexo/).
Parents of children with X(T) participating in a previ-
ous observational cohort study [The Improving Out-
comes in Intermittent Exotropia (IOXT) study] [18,19]
were surveyed and their comments taken into account
in developing the present study, together with input
from the lay group of the Royal College of Ophthalmolo-
gists and the patient and public engagement committee
of the Newcastle NHS Hospitals Foundation Trust.
Comments included the need to carefully explain the
potential risks and benefits of a child with X(T) being in
the active monitoring arm. Overall, comments were sup-
portive of the need for such a study.
Our ultimate goal is to improve the treatment that
children with X(T) receive by evaluating the risks and
benefits of surgery in an RCT in which some children,
where safe to do so, have surgical treatment deferred.
Equally, the trial would enable us to determine whether
some children get better spontaneously and to assess the
effect of the condition and its treatment on quality of life
(QOL). We would also evaluate costs to families and to
the NHS and whether surgery represents a good use of
the resources available.
The specific objectives of the current SamExo pilot
trial are:
1. To determine whether participating centres are likely
to recruit a sufficient number of patients to deliver a
full trial.
2. To determine whether recruited patients will stay
within their allocated groups and complete follow-up
in sufficient numbers to deliver the trial.
3. To identify reasons why parents accept or decline
participation in the trial.
4. To pilot the procedures involved in the trial
including recruitment (giving information and
obtaining consent), randomisation, intervention
(surgery), masking, outcome measurements, and
web-based trial management and data capture
systems.
Methods
Study design
SamExo is a rehearsal pilot randomised controlled
trial (RCT) to assess the feasibility of a full RCT of the
effectiveness of surgical treatment against active moni-
toring in X(T) (Figure 1). The trial is being conducted
according to recommendations for good practice in pilot
studies [35].Study setting
Four secondary ophthalmology care facilities at the
Newcastle upon Tyne NHS Foundation Trust (coordin-
ating site), Sunderland Eye Infirmary, Moorfields Eye
Hospital and York NHS Trust, each of which are large
centres with specialist paediatric ophthalmology clinics.
Participants and sample size
Children aged between 6 months and 16 years referred
to the clinics with suspected X(T) from community
screening, general practice or other health-care profes-
sionals, and subsequently diagnosed with X(T), as well
as existing patients fulfilling the eligibility criteria. The
parent/guardian provides written informed consent for
participation in the study prior to any trial-specific
procedures.
A formal power calculation was not performed for this
feasibility study. It is not powered to detect a clinically
or economically meaningful difference in the primary
outcome between the surgical and active monitoring
groups. Rather, the aim is to provide robust estimates of
the likely rates of recruitment and retention, and to yield
estimates of the variability of the primary and secondary
outcomes to inform power calculations for a subsequent
full-scale RCT. We originally estimated that over a re-
cruitment period of 6 months (subsequently extended to
9 months) across four centres, we would be able to ap-
proach 240 patients who met the entry criteria. From
their responses we would be able to determine whether
the study is acceptable to parents and consequently
whether it is possible to recruit patients and follow them
up. We would also be able to estimate attrition rates. By
approaching 240 children/parents we would be able to
estimate the recruitment rate with a standard error no
larger than 3.3%. Assuming that half of these children
are actually recruited, we will be able to estimate the 6-
monthly attrition rate with a standard error no larger
than 4.3%.
Clinical tests
The following routine clinical assessments are under-
taken at each visit:
 Binocular single vision (BSV) testing − either
stereovision or motor fusion (reflex convergence of
the eyes in response to a base out prism);
 Best corrected visual acuity (VA) on an age-
appropriate test;
 Measurement of the ocular misalignment using the
Alternate Prism Cover Test (APCT);
 Measurement of how well the squint is controlled
using the revised Newcastle Control Score (NCS)
[36] and the Mayo score [37]. The NCS combines
an estimate of observed frequency of the X(T) by
Children with X(T) screened for 
eligibility  (n= 240)
Excluded  (n= 96)
Not meeting inclusion criteria (n= 10)
Refused to participate (n= 80)
Other reasons (n= 6)
Analyzed  (n= 60)
Excluded from analysis  (n=)
Give reasons
Lost to follow-up  (n= 12)
Give reasons
Discontinued intervention (n=)
Give reasons
Allocated to active monitoring (n= 72)
Received allocated intervention (n=)
Did not receive allocated intervention (n=) 
Give reasons
   
   
   
 
Lost to follow-up  (n= 12)
Give reasons
Discontinued intervention (n=)
Give reasons
Allocated to surgery (n= 72)
Received allocated intervention (n=)
Did not receive allocated intervention (n=)
Give reasons
Analyzed  (n= 60)
Excluded from analysis  (n=)
Give reasons
Allocation
Analysis
Follow-Up
Enrolment
n=144
Randomisation
Children identified with suspected X(T) 
Figure 1 SamExo pilot trial design.
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child’s ability to realign the eye following a cover test
to induce misalignment (clinic control for distance
and near fixation) − possible total NCS scores range
from 0–9 (0–3 for home, 0–3 for clinic distance and
0–3 for clinic near control). On the Mayo score, the
distance score (0 to 5) is combined with near score
(0 to 5) to yield an overall control score ranging
from 0 to 10. On both instruments, higher scores
are indicative of poorer control.
Inclusion criteria
 Age between ≥ 6 months and ≤ 16 years
 Evidence of X(T) on the basis of parental history
and clinical examination
 No ongoing or planned amblyopia treatment
 VA of 0.500 or better on an age-appropriate
logMAR-based test or, where uniocular testing is notpossible, central steady maintained fixation when
one eye is occluded
 NCS of ≥ 3
 Minimum of 15 dioptres misalignment in the
distance
 Presence of near stereopsis documented using the
preschool Randot Test if ≥ 3 years of age
 If < 3 years old must be able to overcome a base out
prism (10, 15 or 20^)
Exclusion criteria
 Age over 16 years
 Previous treatment for X(T)
 Constant XT (other than microtropia)
 VA of > 0.500 logMAR in either eye
 X(T) where near misalignment is >10 prism dioptres
more than the distance misalignment
 Structural ocular pathology
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 Families planning to move out of area
Recruitment and consent
Children referred from community screening, general
practice or other health professionals are clinically
assessed in the normal way when they attend their initial
outpatient visit. Where appropriate, glasses are pre-
scribed to correct any refractive error. Discussion about
the management of the X(T) itself includes providing in-
formation about the study and the possibility of taking
part. Parents who express an interest are then given
written information and subsequently telephoned by a
member of the study team to discuss any queries they
may have once they have had time to read the documen-
tation and talk things through with their families. All
parents are given an appointment on a study recruit-
ment clinic. At the recruitment clinic, eligibility is con-
firmed by checking the results of the initial routine
clinical assessment against the inclusion criteria. Eligible
parents are then asked if they would like to enter the
study. Informed consent is obtained from those who de-
cide to participate. Participants are also being identified
from existing lists of patients who are already under
follow-up and fulfil the eligibility criteria; we are adher-
ing to the same information-giving and consent proce-
dures as for new referrals.
The following routine clinical assessments are made in
order to confirm the patient’s eligibility for the trial:
 BSV testing;
 Best corrected VA on an age-appropriate test;
 Measurement of the ocular misalignment using the
APCT;
 Measurement of how well the squint is controlled
using the NCS and Mayo scores.
Eligible families who do not wish to take part in the
trial are asked whether they would consent to come back
for a follow-up appointment after 9 months and allow
us to use routine clinical data from that visit and their
initial visit. Data from those who agree to this will be
used to verify whether the recruited group is representa-
tive and to determine how many of those eligible but
not recruited went on to have surgery during that 9-
month period.
Interventions
Clinic appointments
Figure 2 illustrates the schedule of study visits and cor-
responding assessments for the active monitoring and
surgery arms. The assessments involve routine clinical
measurements together with the evaluation of QOL
using the Intermittent Exotropia Questionnaire (IXTQ)[38], a health services use questionnaire (HSUQ) and a
time and travel questionnaire (TTQ). Children in the ac-
tive monitoring group will be offered surgery if a con-
stant strabismus appears to be developing or parents
request surgery and the responsible clinical team agrees
that this is appropriate.Eye muscle surgery
Surgery is performed by the local principal investigator
(PI), or delegated deputy, according to agreed surgical
formulae tailored to the clinical characteristics of the
strabismus and the usual practice of the surgeon. Princi-
ples involved in the surgical treatment of children in the
study have been agreed as follows:
 General anaesthesia
 Bilateral lateral rectus recession surgery to be
performed for true distance exotropia
 Unilateral recess/resect surgery to be performed for
other types of exotropia
 Standard sterile preparation of the operative site
 Conjunctival incisions
 Standard isolation and cleaning of muscle to be
operated
 Muscle secured with 6/0 vicryl suture
 Amount of recession/resection assessed on the basis
of the maximum distance angle according to table,
modified according to standard practice of surgeon
 Measurement of amount of muscle adjustment to be
checked post placement of scleral sutures
 Conjunctival incisions closed with vicryl sutures
 Topical anaesthetic and antibiotic drops given at the
end of procedure
A surgical table (Table 1) is being used with modifica-
tion as appropriate to determine the amount of eye
muscle movement to be performed depending upon the
size of the angle of exotropia. Surgical technique is care-
fully recorded and monitored during the pilot with a
view to standardising surgical technique, as far as it is
possible to do so, in a full trial and provide a clear de-
scription of the intervention in subsequent reports.Primary outcome visit
The final assessment (9-month outcome) will be con-
ducted by a research orthoptist (RO) who is masked to
the allocation of the child and has not otherwise been in
contact with children enrolled in the study. The parent
and child will be requested not to reveal the group allo-
cation of the child to the RO prior to the assessment.
While children have noticeably red eyes immediately fol-
lowing eye muscle surgery, it is recognised that this red-
ness resolves within 6 weeks when this is a first
Children aged 6 months to 16 years who are:
a) referred from community screening, GPs or other health professionals;
b) existing patients with untreated X(T)
Initial clinic visit for new referrals: routine clinical assessment; 
discussion about management of X(T) and study information 
Telephone call from member of study team to resolve any queries
Recruitment clinic:
Initial clinical data checked to confirm eligibility; informed consent sought; 
centralised web-based randomisation and QOL evaluation
Active Monitoring
3 months after recruitment
3-month monitoring visit
(clinical, HSUQ & TTQ 
assessments by TO)
6 months after recruitment
6-month monitoring visit
(clinical and HSUQ 
assessments by TO)
9 months after recruitment
Blinded 9-month outcome visit
(clinical, QOL and HSUQ 
assessments by RO)
Surgery
3 months after recruitment
Pre-assessment & surgery
within 3 months; 2-week post- 
assessments by TO)
~6 months after recruitment
3-month post-op visit
(clinical, HSUQ and TTQ 
assessments by TO) 
~9months after recruitment
Blinded 6-month post-op
outcome visit (clinical, QOL 
and HSUQ assessments by RO)
         op visit (clinical and HSUQ 
Figure 2 Summary of study visits, assessments and interventions. Abbreviations: HSUQ = health services use questionnaire; QOL = quality of
life; RO = Research orthoptist; TO = treatment orthoptist; TTQ = time and travel questionnaire.
Table 1 Surgical table for use in the SamExo pilot trial
Angle of
deviation
(dioptres)
Lateral rectus
recession
(mm)
Medial rectus
resection
(mm)
Bilateral lateral
rectus recession
(mm)
20 4 3 4.5
25 5 4 5
30 5.5 4 6
35 6.5 4.5 6.5
40 7 4.5 7
50 8 4.5 8
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eye muscle surgery will be inconspicuous by 6 months.
Parent interviews
We are gathering qualitative data (primarily through
telephone interviews) from parents to explore their rea-
sons for either accepting or declining participation in
the pilot study, their thoughts on randomisation and the
study information received, and any ideas they may have
for improving the trial. These data will inform the design
of a full RCT. Whilst the principles of informed consent
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for their decision if they do not want to, we are inviting
parents to take part in a telephone interview if they
agree to this level of involvement. Without this informa-
tion, it is difficult to see how the research design can be
improved to make it more acceptable. These interviews
are being conducted by a university researcher who is
entirely separate from the clinical team, emphasising
that parents’ decisions not to participate have been
respected and reassuring that no attempt is being made
to change their minds.
Randomisation
Randomisation is in permuted blocks stratified by col-
laborating centre, age and severity of X(T) as measured
by the NCS. A blocked allocation (permuted random
blocks of variable length) system is being used to allo-
cate patients to the two groups in a 1:1 ratio to interven-
tion (surgery) and control (active monitoring) groups.
Randomisation is administered using a centralised,
password-protected web-based system, which is mana-
ged by the Newcastle Clinical Trials Unit (NCTU). The
PI at site, or individual with delegated authority, enters
the patient ID, initials and the stratifying variables,
which then return the allocation status. Participants are
informed of their group allocation and given the appro-
priate Group Allocation Information sheet.
Allocation concealment
Since surgery is the intervention of interest it is not pos-
sible to mask participants or parents to their group allo-
cation. Masking of investigators is being achieved by the
designation of a treatment orthoptist (TO) and a RO at
each site. TOs cannot be masked to the group allocation
of participants since they will conduct all assessments
other than the outcome assessment and deal with quer-
ies from parents/children during the course of the trial.
Clinical examination at the primary outcome visit will
be carried out by the ROs who will be unaware of treat-
ment group allocation. At this final study visit, the suc-
cess of the masking will be assessed by asking the
outcome assessor: “Do you think the patient has had
surgery or not? Why do you think this?” Their responses
will be recorded on a separate form.
Proposed outcome measures
For children with X(T), and their parents, the most rele-
vant outcome from intervention is the restoration of
normal eye alignment, with associated cosmetic and
functional benefits. The primary outcome in a full-scale
trial will therefore be the difference in the cure rate of X
(T) between the surgical and actively monitored group;
this is also the primary outcome for which data will be
collected in the current pilot in order to inform samplesize calculations for a definitive RCT. Cure will be
defined as:
 a control score (NCS) of 0 (misalignment never
noticed by parents, no observable deviation on cover
test)
 demonstrable near stereoacuity in children over 3
years of age
Secondary outcomes include age-specific QOL assess-
ments, median scores of control of exotropia assessed by
parental report and clinical components of the NCS and
the Mayo Score, rates of amblyopia, use of health-care
resources, NHS costs, costs to families accessing the
treatments being evaluated and incremental cost per
cured patient (with cure as defined by the primary out-
come), and a cost-consequences analysis based on the
incremental cost with respect to changes in all relevant
outcomes where possible.
The key outcomes of this pilot study are:
 data on the variability of the primary and secondary
outcome measures;
 rates of participant recruitment and randomisation;
 nature and extent of participation bias;
 rates of cross-over and retention of recruited
participants;
 nature and extent of biases arising from cross-over
or loss to follow-up.
An initial recruitment rate of >60% and a retention
rate of >70% will be considered necessary to indicate
feasibility of a full-scale RCT.
Our intention in the full trial would be to conduct a
cost-effectiveness analysis based on incremental cost per
cured patient (as defined by the primary outcome) and a
cost-consequences analysis based on incremental cost
with respect to changes in all relevant outcomes where
possible, including the QOL measure and different clin-
ical measures. In the pilot study, we will rehearse this
cost-effectiveness analysis to inform the study hypothesis
and the analysis plan for the definitive trial. We will also
assess the ease of collecting information on outcome
and costs needed for the health economics analysis.
With respect to collecting costs data, we will pilot the
TTQ and HSUQ that capture patient costs and the NHS
costs. We will assess the response and completion rates
of these instruments. Patient costs will include travel
costs for accessing NHS primary and secondary care;
time costs of travelling and attending NHS primary and
secondary care; and self-purchased health-care and
related management costs. NHS costs will comprise use
of health-care resources in both primary and secondary
care. Total costs consisting of patient costs and the NHS
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interventions.
Statistical methods
For primary outcomes, t-tests and Wilcoxon tests will be
used to compare the age and severity of X(T) of those
participants retained with any withdrawing from the trial
and to compare those who consent with those eligible
but refusing to participate. A chi-square test will be car-
ried out to assess the variability of the primary outcome
(difference in cure rate at the final assessment between
the surgery and active monitoring arm).
For secondary outcomes, non-parametric testing (Wil-
coxon) will be used to compare change over time in me-
dian control scores within the two groups between
baseline and 9-month follow-up (Mann-Whitney tests
will examine any differences between the groups at base-
line and 9 months); rates of development of amblyopia
in the two groups will be determined by monitoring vis-
ual acuity at the 3-, 6- and 9-month assessments. For
the QOL measurements, we are primarily concerned
with response and completion rates for these instru-
ments in both groups; in addition, their validity will be
assessed by matching individual pre- and post-treatment
scores to the post-treatment primary outcome using
t-tests.
Statistical significance will be set at p < 0.05. Data will
be analysed with the SPSS statistical package.
Trial governance
Sunderland Research Ethics Committee (REC) has given
the SamExo pilot trial a favourable ethical opinion
(reference 10/H0904/57). The Newcastle upon Tyne
NHS Hospitals Foundation Trust is acting as the trial
sponsor. A Trial Management Group is overseeing the
overall conduct and progress of the study and provides
day-to-day support to collaborating sites. Training has
been given to collaborators through investigator meet-
ings, site initiation visits and routine monitoring visits.
Quality control is maintained through adherence to the
study protocol, Standard Operating Procedures (SOPs),
principles of good clinical practice, research governance
and clinical trial regulations. As agreed by the sponsor a
Trial Steering Committee (TSC), which includes a par-
ent representative, is adopting the joint roles of TSC and
Data Monitoring & Ethics Committee (DMEC), with in-
dependent members meeting in closed session to fulfil
the DMEC role.
Potential risks and adverse events
This is a low-risk trial and major safety data are not
anticipated. The major identified risk for participants is
that those in the active monitoring arm may experience
a natural deterioration in their clinical condition. Thisrisk will be managed by 3-monthly assessments of the
child for the duration of the study. Children will be
offered treatment if there is a significant deterioration,
or if the parent wishes to discontinue monitoring in
favour of eye muscle surgery and the clinical team agrees
that surgery is appropriate following a discussion of the
risks and benefits, based on currently available informa-
tion. Participation may generate anxiety for some par-
ents and children [39]: this risk will be managed by
providing ready access to sources of advice and support
(for example the TO). Study information provided to
parents and participants includes an account of existing
knowledge of the natural history and current manage-
ment of X(T). Parents are informed that their children
will be regularly assessed and encouraged to report con-
cerns about their child’s X(T) to the TO who will take
these to the local PI. The latter will arrange for eye
muscle surgery if the child meets the usual criteria for
surgery. Parents will be encouraged to report concerns
about the conduct of the study to the Trial Steering
Committee, Sponsor and Funder.
Adverse event reporting following surgery will be
undertaken in accordance with the National Research
Ethics Service (NRES) guidelines for adverse event
reporting in non-CTIMP trials. A serious adverse event
(SAE) in this pilot trial is defined as an untoward occur-
rence that:
 results in death
 is life-threatening
 requires hospitalisation or prolongation of existing
hospitalisation
 results in persistent or significant disability or
incapacity
 is otherwise considered medically significant by the
investigator
Expected adverse events, both common and rare after
X(T) surgery, are listed in Table 2. If a patient experi-
ences an SAE it will be reported to Sunderland REC
when, in the opinion of the chief investigator, the event
was ‘related’: that is, resulted from administration of any
of the research procedures; and ‘unexpected’: that is, the
type of event is not listed in the protocol as an expected
occurrence. Any SAEs will be reported to the NCTU
within 24 h of the PI learning of its occurrence. Reports
of related and unexpected SAEs will be submitted to the
REC within 15 days of the chief investigator becoming
aware of the event, using an NRES ‘report of serious ad-
verse event’ form.
Discussion
The optimum management of X(T) in children is con-
tentious, with some clinicians recommending early
Table 2 Expected adverse events during the SamExo pilot
trial
Procedure Adverse event:
Common & well
understood
consequences
of treatment
Rare events
Perforation of the globe Occurring within
24 h
Occurring after
24 h
Intraocular infection Occurring within
2 weeks
Occurring after
2 weeks
Lost or slipped muscle Occurring within
1 month
Occurring after
1 month
Scleritis Occurring within
1 month
Occurring after
1 month
Becoming constant XT Occurring within
9 months
Occurring after
9 months
Persistent over-correction Occurring within
9 months
Occurring after
9 months
Re-operation for under-
or over-correction
Occurring within
9 months
Occurring after
9 months
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actively monitor. The lack of robust evidence to guide
management and the poorly understood natural history
of this condition renders it difficult for clinicians to offer
clear advice to parents. Consequently, many children are
observed without any treatment for extended periods be-
cause of the uncertainty surrounding the best course of
action. The need for evidence from randomised studies
has been acknowledged for some time now [27], and this
is the first attempt, as far as we are aware, to explore the
potential for a RCT of surgery versus active monitoring
in childhood X(T). We felt it would be inappropriate to
undertake a full-scale study involving large numbers of
participants and centres before first conducting a feasi-
bility study. The SamExo pilot study will provide import-
ant pointers regarding how acceptable a RCT of
immediate surgery versus deferred surgery/active moni-
toring will be to participants and clinicians.
The recruitment phase will give us a good indication
of the proportion of eligible children/parents who would
sign up to a full trial, the likelihood of them withdrawing
from it and also an idea of how many we would need to
approach over a given duration to achieve a specified
sample size.
Equally pivotal will be the reasons why parents agree
or decline the pilot trial, their perceptions of the need
for and purpose of randomisation, their views on the na-
ture of the information they received, and suggestions
for improving future trials and refining the research
question. Findings from these qualitative interviews will
not only inform the design of a possible full trial but
may also help investigators planning studies of surgicalinterventions, trials of other children’s eye conditions or
paediatric trials in general.
Potential ethical issues include the fact that some of
the children in the SamExo pilot study will be asked to
wait up to 9 months before being offered surgery. We
feel that this can be justified as our previous work has
shown that less than 8% of children with X(T) had sur-
gery within the first year following initial assessment
when treated in a routine setting [18]; in some centres,
no children had surgery within 2 years of diagnosis [19].
Children who have very mild X(T) are not being entered
into the trial, even though our earlier research found
that some of these children did have surgery. Similarly,
we are not recruiting children who appear to be at
imminent risk of developing a constant squint. Children
who are in the active monitoring arm are being regularly
assessed and will be offered treatment if they develop, or
seem to be at risk of developing, a constant squint. With
increased rates of surgery, we may see increased rates of
re-operations, persistent over-correction and other sur-
gical complications.
Trial status
Recruitment to the SamExo pilot trial commenced in
September 2011 and is ongoing at the time of manu-
script submission. Recruitment was originally scheduled
to end in February 2012 but we have extended this
phase up to 31 May 2012. (The total duration of the trial
is unchanged.) This extension to recruitment was
recommended by the TSC in January 2012 and agreed
upon by the funders in light of early indications that
fewer screened patients were actually eligible for the
study and fewer eligible patients had thus far agreed to
participate than was predicted.
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